|
|
| |
Gemcitabine for Injection USP 200 mg |
| |
Pancreatic Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Bladder Cancer
Ovarian Cancer
Oesophageal Cancer
|
| |
Single-Agent Use : Pancreatic Cancer — Gemcitabine should be administered by intravenous
infusion at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks
(or until toxicity necessitates reducing or holding a dose), followed by a week
of rest from treatment.
Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out
of every 4 weeks.
Combination Use
Non-Small Cell Lung Cancer : Two schedules have been investigated
and the optimum schedule has not been determined.
With the 4-week schedule, Gemcitabine should be administered intravenously
at
1000 mg/m2 over 30 minutes on days 1, 8 and 15 of each 28-day cycle.
Cisplatin should be administered intravenously at 100 mg/m2 on day 1 after
the infusion of Gemcitabine.
With the 3-week schedule, Gemcitabine should be administered intravenously
at 1250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle.
Cisplatin
at a dose of 100 mg/m2 should be administered intravenously after the infusion
of Gemcitabine on day 1.
Breast Cancer : Gemcitabine should be administered intravenously at a dose
of 1250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Paclitaxel
should be administered at 175 mg/m2 on day 1 as a 3-hour intravenous infusion
before Gemcitabine administration.
Ovarian Cancer : Gemcitabine should be
administered intravenously at a dose of 1000 mg/m2 over 30 minutes on
days 1 and 8 of each 21-day cycle. Carboplatin AUC 4 should be administered
intravenously on day 1 after Gemcitabine administration.
Dosage Adjustment :
Renal Impairment : Administer with caution.
Hepatic Impairment : Administer with caution. |
| |
Packing : |
5 Vials of 200 mg |
|
|
